Cancer drug developer Endocyte files for IPO
The company, headquartered at Purdue Research Park, said the number of shares to be offered and their price range have yet
to be determined.
Health Care & Insurance
Articles
Lilly Alzheimer’s drug prospect only the latest to fail
A dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
Bad news piles up for Lilly
What a tough week for Lilly. On Aug. 12, a judge struck down the Indianapolis-based drugmaker’s U.S. patent on Strattera,
which might cost the company about $450 million in annual revenue. Then, five days later, Lilly halted clinical trials on
one
of its experimental Alzheimer’s medicines, because patients did worse on the drug than on a placebo.
Q&A
Dr. Kevin Macadaeg, vice president of the Indiana Spine Group, talked about his physician
group's decision to build a 60,000-square-foot medical office and "bioskills" lab in Carmel next year, as well
as the group's commitment to grow independently in the face of pressures from hospital acquisitions and health reform.
Expanding hospitals target Bloomington
Monroe Hospital in Bloomington is the latest target in the statewide buildup by hospital systems. St. Vincent Health, St.
Francis and at least one other system have all had talks in the past month with Monroe.
Visteon ordered to reinstate health care to retirees
The mandate from a U.S. bankruptcy judge will supply retroactive benefits to more than 6,000 Visteon Corp. retirees who lost
insurance coverage after
the
Michigan-based auto-parts maker filed for bankruptcy in 2009, including 2,100 workers in Indiana.
Lilly’s Cymbalta helps chronic pain in U.S. review
Approval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta’s
annual sales.
Lilly halts development of Alzheimer’s drug
Studies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
Eli Lilly loses patent lawsuit for Strattera
Eli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention
deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
WellPoint, other health insurers race to join accountable care groups
The health care industry is responding to reforms that will pay doctors bonuses if they provide high-quality care and save
Medicare money.
Life sciences panel pegs bright spots in Indiana
Leaders tackle issues ranging from research to cold storage to the future of Eli Lilly and Co.
For Lilly, it’s a big one that got away
An experimental medicine for hepatitis C that Lilly helped identify and develop is now on the cusp of market approval, with
analysts predicting as much as $2 billion in annual U.S. sales.
Roche hit with new breed of patent suit
Roche Diagnostics, a Swiss company that keeps its U.S. headquarters in Indianapolis, has been sued for marking its Accu-Chek
blood glucose monitors and accessories with patents that are expired. Illinois resident David O’Neill has sued on behalf
of the U.S. government to recover damages of $500 per infraction.
WellPoint boosts debt offering to $1 billion
Proceeds from the sale will be used for working capital and general corporate purposes, including debt repayment, the company
said in a prospectus.
Arcadia sees smaller loss, extends WellPoint pact
Indianapolis-based health care firm reaches agreement to offer its DailyMed product to more WellPoint Inc. health plan members.
Indiana gets $2.3M for electronic health records
Medicaid Director Pat Casanova says the money will be used for necessary state steps to create an incentive program for medical
providers and hospitals to move from paper records to electronic ones.
Court defeat lost in Lilly’s gloomy long-term outlook
Eli Lilly and Co.’s loss of a patent on one of its blockbuster drugs in court late last month received a collective yawn
from
investors, who have shunned the stock because of five looming patent expirations.
CNO Financial profits surge 20 percent, beating expectations
The Carmel-based life and health insurer earned $33.1 million in the three months ended June 30, or 12 cents per diluted share.
Excluding losses on investments and retired debt, the company would have earned 16 cents per share.
Analyst: Arcadia sales poised to take off
Arcadia Resources’ DailyMed business will grow revenue 10-fold in the next three years and push the Indianapolis-based
company into profitability, according to a research report by the first analyst to officially cover the company.
Former commerce chief lands at local company
Nate Feltman, former state secretary of commerce, has left his partnership position at Baker & Daniels LLP to become president
of Home Health Depot LLP, a
growing home-medical-equipment supplier.